Douglas Buckley

Douglas Buckley, Ph.D. joined 3-V Biosciences as Vice President, Biology in June 2012. Buckley has over 25 years of experience in the biopharmaceutical industry, most recently as Vice President of Biochemistry at Exelixis Inc. Also during his tenure at Exelixis, he served as Discovery representative to the cabozantinib (XL 184) Global Filing Team with responsibility for coordinating and editing all Discovery Reports included in the NDA filing. Prior to Exelixis, Dr. Buckley was the Department Head of Protein Chemistry and Process Development at Scios, Inc., where he was responsible for process and assay development for two marketedbiotherapeutic products (Fiblast® (trafermin) and NATRECOR® (nesiritide)). Doug received his AB in Chemistry and Economics from Bowdoin College, his Ph.D. in Endocrinology from the HormoneResearch Laboratory at the University of California, San Francisco, and hispost-doctoral training in the Molecular Biology Department at MassachusettsGeneral Hospital and the Department of Genetics at Harvard Medical School.